Abstract
Background Metabolic syndrome (MetS) is one of the major factors for cardiometabolic comorbidities in people living with HIV (PLWH). The long-term consequences of HIV-infection and combination antiretroviral therapy (cART) in metabolic reprogramming are unknown. In this study, we aim to investigate metabolic alterations in long-term well-treated PLWH with MetS to identify the potential mechanism behind the MetS phenotype using advanced statistical and machine learning algorithms.
Methods We included 200 PLWH ≥40 years old from the Copenhagen Comorbidity in HIV-infection (COCOMO) study. PLWH were grouped into PLWH with MetS (n=100) and without MetS (n=100). The clinical data were collected from the COCOMO database and untargeted plasma metabolomics was performed using ultra-high-performance liquid chromatography/mass spectrometry (UHPLC/MS/MS). Both clinical characteristics and plasma samples were collected at study baseline. We applied several conventional approaches, machine learning algorithm and linear classification model to identify the biologically relevant metabolites associated with MetS in PLWH.
Findings A total of 877 characterized biochemicals were identified. Of these, 9% (76/877) biochemicals differed significantly between PLWH with and without MetS (false discovery rate <0.05). The majority belonged to the amino acid metabolism (n=33, 43%). A consensus identification by combining supervised and unsupervised methods indicates 11 biomarkers of MetS phenotype in PLWH, of which seven (63%) have higher abundance in PLWH with MetS compared to the PLWH without MetS. A weighted co-expression network by Leiden partitioning analysis identified seven communities of positively intercorrelated metabolites, of which a single community contained six of the potential biomarkers mainly related to glutamate metabolism (glutamate, 4-hydroxyglutamate, α-ketoglutamate and γ-glutamylglutamate).
Interpretation Altered amino acid metabolism is a central characteristic of PLWH with MetS and a potential central role for glutamate metabolism in establishing this phenotype is suggested.
Funding Rigshospitalet Research Council, Danish National Research Foundation (DNRF126) NovoNordisk Foundation, the Swedish Research Council (2017-01330 and 2018-06156)
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Rigshospitalet Research Council, Danish National Research Foundation (DNRF126) NovoNordisk Foundation, the Swedish Research Council (2017-01330 and 2018-06156)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval was obtained by the Regional Ethics Committee of Copenhagen (COCOMO: H-15017350).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data available within the manuscript.
